



FORESIGHT BIOTHERAPEUTICS ESTABLISHES SCIENTIFIC ADVISORY BOARD

New York, N.Y., September 30, 2009 – Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of its lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight's Scientific Advisory Board is comprised of leaders in the field of Ophthalmology. These highly regarded experts will advise the company on its clinical programs, regulatory strategy and provide strategic guidance to support the development of FST-100 in multiple indications.

The Scientific Advisory Board consists of the following leading Ophthalmologists:

Eduardo C. Alfonso, M.D. Dr. Alfonso is the Chairman of the Bascom Palmer Eye Institute. He is also a Professor in Ophthalmology and holds the Kathleen and Stanley J. Glaser Chair in Ophthalmology at the Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine.

Sherwin J. Isenberg, M.D. Dr. Isenberg is a Professor of Ophthalmology and Vice-Chairman, Department of Ophthalmology at the Ronald Reagan UCLA Medical Center (Jules Stein Eye Institute) and holds the Laraine and David Gerber Endowed Chair in Ophthalmology.

Richard L. Lindstrom, M.D. Dr. Lindstrom is the founder and an attending surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology.

Francis S. Mah, M.D. Dr. Mah is an Assistant Professor of Ophthalmology at the University of Pittsburgh and Medical Director of Charles T. Campbell Ophthalmic Microbiology Laboratory.

Terrence O'Brien, M.D. Dr. O'Brien is a Professor of Ophthalmology and holds the Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami, Miller School of Medicine, where he is Co-Director of the Ocular Microbiology Laboratory.

William Trattler, M.D. Dr. Trattler is a Director of Cornea at the Center for Excellence in Eye Care in Miami, Florida. He is also a Volunteer Assistant Professor of Ophthalmology at the University of Miami's Bascom Palmer Eye Institute.

Foresight Biotherapeutics looks forward to working with the Scientific Advisory Board to advance the development of FST-100.

About Foresight Biotherapeutics, Inc.

Foresight Biotherapeutics is a drug development company focused on diseases of the eye and ear. The company's website is: www.foresightbiotherapeutics.com.

For further information contact:
Investor Relations, Foresight Biotherapeutics
646-747-9100 or admin@foresightbio.com

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Foresight relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Foresight's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Foresight and/or its partners to develop, manufacture and commercialize, Foresight's ability to fund such efforts with or without partners, and other risks.

#